Trials / Completed
CompletedNCT00849290
Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)
AN OPEN LABEL, SINGLE ARM TRIAL OF IMMUNOTHERAPY WITH AUTOLOGOUS ANTIGEN PRESENTING CELLS LOADED WITH PA2024 (APC8015F) FOR MEN WITH OBJECTIVE DISEASE PROGRESSION ON PROTOCOL D9902 PART B
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 113 (actual)
- Sponsor
- Dendreon · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, Phase 2 trial of APC8015F immunotherapy in men with objective disease progression on protocol D9902 part B (NCT00065442)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | APC8015F | APC8015F is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. APC8015F consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein. |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2009-01-01
- Completion
- 2009-04-01
- First posted
- 2009-02-23
- Last updated
- 2023-11-29
- Results posted
- 2010-10-11
Locations
58 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00849290. Inclusion in this directory is not an endorsement.